BCC 2021 | 5-year DMFS outcomes in the NBREaST II trial

Miranda Kleijn, PhD, Agendia, Amsterdam, Netherlands, shares the 5-year follow-up results of the NBREaST II trial, assessing the use of MammaPrint and BluePrint genomic signature testing for neoadjuvant treatment decisions in breast cancer. Previously reported trial findings demonstrated that MammaPrint and BluePrint accurately predicted rates of pathological complete response (pCR) and partial response (PR) to neoadjuvant endocrine therapy. The preliminary findings of the 5-year analysis presented at the St. Gallen Breast Cancer Conference 2021 showed that pCR following neoadjuvant treatment was predictive of increased distant metastasis-free survival (DMFS), with 5-year DMFS rates of 89.7% and 80.6% in the pCR and PR groups, respectively. This interview took place during the 17th St. Gallen International Breast Cancer Conference.